Published ahead of print on October 29, 2004, doi:10.1164/rccm.200406-758OC
American Journal of Respiratory and Critical Care Medicine Vol 171. pp. 115-120, (2005)
© 2005 American Thoracic Society
doi: 10.1164/rccm.200406-758OC
Brain-derived Neurotrophic Factor in Platelets and Airflow Limitation in Asthma
Marek Lommatzsch,
Katharina Schloetcke,
Jens Klotz,
Katharina Schuhbaeck,
Doerte Zingler,
Christiana Zingler,
Olaf Schulte-Herbrüggen,
Hartmut Gill,
Peter Schuff-Werner and
Johann Christian Virchow
Department of Pneumology and Institute of Clinical Chemistry and Pathobiochemistry, University of Rostock, Rostock; Department of Neurology, Charité, Berlin, Germany
Correspondence and requests for reprints should be addressed to Marek Lommatzsch, M.D., Abteilung für Pneumologie, Klinik und Poliklinik für Innere Medizin, Universität Rostock, Ernst-Heydemann-Str. 6, Rostock 18057, Germany. E-mail: marek.lommatzsch{at}med.uni-rostock.de
Brain-derived neurotrophic factor (BDNF), a key mediator of neuronal plasticity, contributes to airway obstruction and hyperresponsiveness in a model of allergic asthma. BDNF is stored in human platelets and circulates in human plasma, but the significance of BDNF in this compartment is poorly understood. We investigated the relationship between platelet and plasma BDNF levels and pulmonary function in a cohort of 26 adult patients with recently diagnosed allergic asthma. BDNF levels in serum, platelets, and plasma were significantly increased in participants with asthma, as compared with 26 age- and sex-matched control subjects. In steroid-naive patients, but not in patients using inhaled corticosteroids, enhanced platelet BDNF levels correlated with parameters of airway obstruction and airway hyperresponsiveness to histamine. Experiments with activated peripheral blood mononuclear cells revealed that corticosteroids such as fluticasone effectively suppress BDNF secretion. In conclusion, we demonstrate that enhanced platelet BDNF is associated with airflow limitation and airway hyperresponsiveness in asthma. In addition, we provide evidence that corticosteroids suppress BDNF production by activated immune cells.
Key Words: airway hyperresponsiveness corticosteroids neurotrophins peak expiratory flow
This article has been cited by other articles:

|
 |

|
 |
 
C. Page
The {beta}2 receptor and airway hyper-responsiveness: are sensory nerves involved?
Thorax,
September 1, 2009;
64(9):
738 - 739.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M Lommatzsch, Y Lindner, A Edner, K Bratke, M Kuepper, and J C Virchow
Adverse effects of salmeterol in asthma: a neuronal perspective
Thorax,
September 1, 2009;
64(9):
763 - 769.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Montuschi, G. Pagliari, and L. Fuso
Pharmacotherapy of asthma: regular treatment or on demand?
Therapeutic Advances in Respiratory Disease,
August 1, 2009;
3(4):
175 - 191.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Zhang, R.-L. Lin, M. Wiggers, D. M. Snow, and L.-Y. Lee
Altered expression of TRPV1 and sensitivity to capsaicin in pulmonary myelinated afferents following chronic airway inflammation in the rat
J. Physiol.,
December 1, 2008;
586(23):
5771 - 5786.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E. Wenzel and R. Covar
Update in asthma 2005.
Am. J. Respir. Crit. Care Med.,
April 1, 2006;
173(7):
698 - 706.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. P. O'Sullivan and A. D. Michelson
The Inflammatory Role of Platelets in Cystic Fibrosis
Am. J. Respir. Crit. Care Med.,
March 1, 2006;
173(5):
483 - 490.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R Staats, P Stoll, D Zingler, J C Virchow, and M Lommatzsch
Regulation of brain-derived neurotrophic factor (BDNF) during sleep apnoea treatment
Thorax,
August 1, 2005;
60(8):
688 - 692.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society
|
|
|